Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTK | P29376 | 3/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.60 |
| ▸ | KDR | P35968 | 2/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.60 |
| ▸ | MARK3 | P27448 | 2/20 | 0.60 |
| ▸ | ROS1 | P08922 | 1/20 | 0.60 |
| ▸ | FLT4 | P35916 | 1/20 | 0.60 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.60 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.60 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.60 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.60 |
| ▸ | PIM1 | P11309 | 3/20 | 0.54 |
| ▸ | PLK4 | O00444 | 2/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.54 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807713 | 0.91 | LTK (0.54) | LTKAURKBKDRCHEK2MARK3 | |
| SCHEMBL4815206 | 0.76 | LTK (1.00) | LTKAURKBKDRCHEK2MARK3 | |
| SCHEMBL4809739 | 0.73 | LMNA (0.48) | LTKAURKBKDRCHEK2MARK3 | |
| SCHEMBL9797806 | 0.72 | KCNJ1 (0.42) | KCNJ1KMT2AMAPT | |
| SCHEMBL4811188 | 0.72 | LTK (0.60) | LTKAURKBKDRCHEK2MARK3 | |
| SCHEMBL4814005 | 0.72 | KCNJ1 (0.36) | KDRKCNJ1CHEK1CDK1CDK2 | |
| SCHEMBL2920391 | 0.71 | LTK (1.00) | LTKAURKBKDRCHEK2MARK3 | |
| SCHEMBL31689734 | 0.69 | ALDH1A1 (0.43) | KCNJ1KMT2AMAPT | |
| SCHEMBL6014179 | 0.69 | ALDH1A1 (0.43) | KCNJ1KMT2AMAPT | |
| SCHEMBL6937611 | 0.69 | MAPT (0.48) | KCNJ1MAPK1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| EP-1603885-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004080973-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | LTK 113/4885AURKB 87/4885KDR 666/4885 |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | LTK 265/4885AURKB 204/4885KDR 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.